BIOMARIN PHARMACEUTICAL: ONE STOCK I WOULD BUY TODAY

By Sudheer Narasimha, Equity Analyst 

There are many Biotech stocks to consider when someone thinks about purchasing. However, in order to build wealth, the company MUST have a bright future ahead of it. Also, for the average investor, it is best if the stock isn’t so volatile. There has to be a stock that has a bright future, and seems to be safe. Does something like this really exist? 

It does and the company is called BioMarin Pharmaceutical. BioMarin Pharmaceutical Inc. is a pioneering biotechnology company at the forefront of developing advanced therapies for rare genetic diseases and serious medical conditions. Established in 1997 and headquartered in San Rafael, California, BioMarin has consistently demonstrated a commitment to pushing the boundaries of science and medicine to address unmet needs within the medical community. With a dedicated focus on rare diseases, the company has garnered recognition for its groundbreaking research, innovative therapies, and patient-centric approach. Through a combination of cutting-edge research, strategic partnerships, and a dedication to improving the lives of those affected by rare disorders, BioMarin continues to play a pivotal role in shaping the landscape of modern biopharmaceutical development. BioMarin Pharmaceutical Inc. stands out as a stellar company due to its unwavering dedication to addressing the unique challenges posed by rare genetic diseases. The company’s commitment to scientific excellence is evident in its consistent production of groundbreaking therapies that have transformed the lives of countless patients worldwide. By concentrating on rare diseases, BioMarin fills critical gaps in medical treatment that are often overlooked by larger pharmaceutical entities. This targeted focus allows the company to allocate resources more effectively, resulting in a stream of innovative treatments that offer tangible benefits to patients and their families. Moreover, BioMarin’s collaborative approach, partnering with patient communities, medical professionals, and research institutions, demonstrates a genuine commitment to improving patient outcomes and advancing medical knowledge.

Niche Products for Big Needs 

We can go even further into this by taking a look at their pipeline. BioMarin Pharmaceutical Inc.’s robust pipeline reflects its continuous commitment to innovation and addressing unmet medical needs in the realm of rare genetic diseases. These are diseases that only effect a small group of people, but that small group often suffers disproportionately. One example would be the notorious disease Hemophilia A. This genetic defect causes patients to bleed uncontrollably, and may even have been responsible for the fall of the Russian Empire. Now, for the first time, BioMarin is offering a medication that fixes the genetic defect and essentially cures the dread disease.  By eradicating this small disease, BioMarin hopes to make a big impact on human health. 

With a strategic focus on advancing therapies from early-stage research to late-stage development, the company’s pipeline showcases a diverse range of potential treatments across various medical conditions. This includes investigational gene therapies, enzyme replacement therapies, and small molecule compounds designed to target the underlying causes of these rare disorders. BioMarin’s dedication to pushing the boundaries of science is exemplified by its pursuit of cutting-edge technologies and collaborations with experts in the field. By harnessing the power of genetics, precision medicine, and advanced therapeutic modalities, the pipeline demonstrates the company’s vision of bringing transformative solutions to patients who have long been underserved by traditional medical approaches. BioMarin Pharmaceutical Inc.’s carefully curated and innovative pipeline holds the promise of substantial profitability in the future, driven by several key factors. First and foremost, the pipeline’s focus on rare genetic diseases taps into a niche market with limited treatment options, often affording the company a competitive advantage and potential pricing flexibility. Moreover, the strong emphasis on advanced therapies, such as gene therapies and precision medicine, positions BioMarin at the forefront of scientific and technological advancements, allowing it to command premium pricing for cutting-edge treatments. Additionally, the company’s strategic collaborations and partnerships not only enhance the pipeline’s breadth and depth but also distribute development costs and risks, potentially leading to a more efficient and cost-effective path to market. As these therapies progress through clinical trials and gain regulatory approvals, BioMarin’s position as a leader in the rare disease space further solidifies, potentially fostering investor confidence and attracting further capital.

Sound Medicine, Sound Money 

More than their pipeline, something else that really stands out about BioMarin is their current profitability. Many other BioTech companies usually operate at a loss which makes it so they have to rely on continued fund raising to ward off the danger of running out of funds. However, BioMarin has a big advantage in that they can fund their own research through the profits they make. Going into their financials, we can see that BioMarin had a very strong second quarter in 2023. Their total revenue was up 12% and their GAAP net income increased by $23.8 million while their non-GAAP income increased by $28.4 million. The future is bright….the company boasts gross profit margins of 78%, and has about $1.6 billion in the bank. Plenty of dry powder to push promising research to its conclusion and bring lucrative products to market. 

Investors should consider BioMarin Pharmaceutical Inc. as an appealing investment opportunity due to its unique position at the intersection of cutting-edge science, rare disease specialization, and a demonstrated track record of innovation. With a pipeline showcasing a diverse range of advanced therapies, including gene therapies and precision medicines, BioMarin is positioned to capitalize on the growing demand for transformative treatments. The company’s history of successful drug development and commercialization underscores its ability to bring therapies from concept to market fruition. As BioMarin’s therapies progress through clinical milestones, investor confidence could increase, potentially leading to significant returns. Also, their current profitability and future sustained profitability is a huge plus for their research since they can fund themselves. For those seeking a blend of scientific innovation, market potential, and ethical investment, BioMarin Pharmaceutical Inc. stands as a compelling option in the biopharmaceutical landscape.